Highlights

  • Q3 FY2026 Revenue increased 11% to $1.4 billion (8% on a constant currency basis), driven by strong Demand across sleep devices, masks and accessories.
  • GAAP gross Margin expanded 290 basis points to 62.2%; non-GAAP diluted EPS of $2.86, up 21% year-on-year.
  • Operating Cash Flow of $554 million; quarterly Dividend of $0.60 per share declared with a Record Date of 14 May 2026.

ResMed CDI units (ASX:RMD) traded at AUD 29.60 on 1 May 2026, declining AUD 0.18, or 0.60%, during the session. The modest pullback is somewhat at odds with what were genuinely strong Q3 FY2026 financial results released on 30 April 2026, reflecting a common market dynamic where strong but expected results prompt modest profit-taking rather than a significant price re-rating. ResMed, as one of the highest-quality healthcare companies listed on the ASX, trades at a premium valuation, and incremental Earnings beats at the Margin are often already reflected in the price by the time results are formally published.

Revenue Performance: Broad-Based Growth

ResMed reported total Revenue of $1.4 billion for the third quarter of fiscal year 2026, representing an 11% increase from the prior year period. On a constant currency basis — stripping out the impact of foreign exchange movements, particularly the Depreciation of several major currencies against the US dollar — growth was 8%, still a robust result for a company of ResMed's scale. The growth was broad-based across geographies and product categories, reflecting both structural Demand for sleep disorder treatment products and ResMed's strong commercial execution.

In the US, Canada and Latin America (excluding Residential Care Software), Revenue grew 9%. European, Asian and other markets (excluding Residential Care Software) contributed constant currency growth of 7%. The Residential Care Software segment, which serves aged care and home health operators, delivered a more modest 4% constant currency growth rate — a segment that continues to face a different Demand and competitive dynamic from the core device and mask Business.

Gross Margin Expansion: The Standout Metric

The headline metric that stands out in ResMed's Q3 results is the 290 basis point expansion in gross Margin, with the GAAP gross Margin rising to 62.2% and the non-GAAP gross Margin to 62.8%. This Margin expansion was driven by three main factors: component cost improvements (reflecting favourable pricing from suppliers as semiconductor and electronic component Supply chains have normalised post-Pandemic), Manufacturing and logistics efficiencies, and a small positive contribution from product mix and foreign currency movements.

For a hardware Business such as ResMed, where device gross margins are intrinsically linked to the cost of electronic components and precision Manufacturing, a 290 basis point improvement in a single quarter is a meaningful structural improvement. It signals that the post-Pandemic cost Inflation that compressed margins across the medical device sector has materially reversed for ResMed, and that the company's scale and Supply chain relationships are translating into genuine cost advantages.

Operating Earnings and EPS: Strong Delivery

ResMed's GAAP income from operations increased by 17% compared to the prior year period, while non-GAAP income from operations grew by 18%. Net Income for the quarter was $399 million, producing GAAP diluted Earnings per share of $2.74. On a non-GAAP basis — which excludes Acquisition and portfolio review related expenses and other adjustments — Net Income was $417 million and diluted EPS was $2.86, representing a 21% year-on-year increase. The 21% non-GAAP EPS growth outpaced the 8% constant currency Revenue growth, demonstrating strong Operating Leverage in the Business model as Revenue scales without a proportional increase in costs.

Selling, general and administrative expenses increased by 11% on a constant currency basis. The increase was attributable to costs associated with the recent VirtuOx Acquisition, employee costs, Marketing investments and technology outlays. SG&A expenses as a percentage of Revenue, excluding Acquisition and portfolio review related costs, came in at 19.5% — slightly above the 19.0% in the prior year period, a modest increase that reflects the deliberate Investment in growth rather than any structural cost inefficiency.

Cash Flow: A Capital-Generative Engine

Operating Cash Flow for the quarter was $554 million, significantly exceeding both GAAP Net Income of $399 million and non-GAAP Net Income of $417 million. This conversion of Earnings into cash reflects the Capital-light nature of ResMed's recurring Revenue streams — particularly its cloud-connected device subscriptions and mask/accessories consumable cycle — as well as effective working Capital management. The company deployed its Cash Flow purposefully: $87 million was paid in dividends to shareholders, and 673,000 shares were repurchased for $175 million as part of the ongoing Capital management programme.

Dividend Declared and CDI Implications

ResMed's board declared a quarterly cash Dividend of $0.60 per share (USD), with a Record Date of 14 May 2026 and a payment date of 18 June 2026. For ASX CDI holders — who hold interests in the company at a 10:1 ratio relative to NYSE shares — the equivalent Dividend will be paid in Australian dollars at the Exchange Rate prevailing on the Record Date. The ex-Dividend date for both NYSE stockholders and ASX CDI holders is 13 May 2026. ResMed has received an ASX Waiver to defer share and CDI register conversions from 13 to 14 May 2026 inclusive.

Operational Highlights: Products and Expansion

Beyond the financial results, ResMed announced several operational developments. The company unveiled findings from its sixth annual Global Sleep Survey, drawing insights from 30,000 respondents across 13 countries — a Marketing initiative that reinforces ResMed's Brand authority in the sleep health space and creates awareness of untreated sleep disorders that represent future Revenue opportunities. The company also announced the expansion of its US distribution infrastructure, with a new centre in Greenwood, Indiana, scheduled to open in 2027 to support growing North American Demand. On the product side, the AirTouch F30i Comfort full face mask was launched in the US, building on prior launches in Australia and Canada.